AOD-9604 Peptide: Mechanism, Toxicology & Oncology Research

AOD-9604 is a synthetic hexadecapeptide fragment derived from the C-terminal region of human growth hormone (hGH), corresponding to residues 176–191 with an added N-terminal tyrosine for structural stability. In some research literature this compound is also referred to as Fragment 176-191, though naming conventions vary between sources. This article covers its molecular structure, lipolytic mechanism, clinical tolerability data, and emerging research in tissue biology and oncology, distinguishing evidence quality and species/model type throughout.

Key Facts at a Glance

Molecular Characterization and Discovery History

AOD-9604 was developed by researchers at Monash University, Australia, who identified the C-terminal fragment of hGH as the domain responsible for its lipolytic activity, distinct from the N-terminal/central domains responsible for receptor binding and IGF-1 stimulation.

The compound's name reflects its origin as an "Anti-Obesity Compound" candidate. An earlier fragment, AOD9401 (residues 177–191), was found to mimic the lipolytic activity of intact hGH in isolated adipose tissue — stimulating hormone-sensitive lipase and reducing acetyl-CoA carboxylase activity — without inducing the insulin resistance or glucose intolerance associated with full-length hGH in preclinical models [3]. Adding an N-terminal tyrosine residue produced the current compound, AOD-9604, with the cyclic disulfide structure thought to contribute to conformational rigidity and degradation resistance [1].

Mechanism of Action

AOD-9604 is proposed to stimulate lipolysis and reduce lipogenesis in adipose tissue through pathways that appear at least partially independent of the canonical hGH receptor and unrelated to serum IGF-1 elevation.

• Research indicates AOD-9604 may stimulate lipolytic processes via oxidative and beta-adrenergic receptor-dependent pathways, without detectable effects on caloric intake, insulin concentrations, or glucose tolerance [2].
• Mechanistic studies suggest AOD-9604 may upregulate β3-adrenergic receptor (β3-AR) expression in adipocytes, potentially contributing to increased lipolytic sensitivity [2].
• Findings in β3-AR knockout models indicate AOD-9604 retains lipolytic activity even without functional β3-AR, pointing to additional receptor-independent mechanisms, possibly involving energy expenditure and fat oxidation pathways [2].
• In vitro research suggests AOD-9604 may also engage cellular differentiation pathways in mesenchymal stem cells, chondrocytes, and myoblasts — pointing to potential pleiotropic activity beyond its lipolytic mechanism [6].

Research Findings by Study

Lipolytic Activity in Obese and β3-AR Knockout Mice

A foundational study examined chronic AOD-9604 exposure in obese mice and in genetically modified mice lacking functional β3-adrenergic receptors. Chronic exposure in obese mice was associated with reduced fat accumulation and weight gain relative to untreated controls, alongside elevated β3-AR expression in treated animals' adipocytes. Critically, AOD-9604 retained lipolytic activity in β3-AR knockout mice, indicating the peptide engages additional receptor-independent mechanisms rather than acting through a single pathway [2].

Metabolic Studies in Obese Zucker Rats

An early study evaluated AOD-9604 in obese Zucker rats, a validated rodent model of obesity characterized by leptin receptor deficiency. Over a 19-day exposure period, treated rats showed a reduction exceeding 50% in weight gain relative to controls, with histological evidence of elevated adipocyte lipolytic activity. Insulin sensitivity parameters remained largely unaltered in treated animals, consistent with a lipolytic mechanism independent of insulin signaling and diverging from intact hGH, which is associated with insulin resistance in preclinical models at comparable concentrations [3].

Phase IIa Human Trial (Press-Reported, Not Peer-Reviewed)

A multi-arm Phase IIa randomized trial reportedly enrolled 300 human subjects with obesity across five AOD-9604 dose arms and a placebo control over 12 weeks. The lowest-dose group showed the most pronounced mean weight reduction (~2.8 kg vs. ~0.8 kg for placebo), with fat reduction reported as consistent across the study duration without an observed plateau [9]. This specific trial's results are sourced from a 2004 news report rather than a peer-reviewed journal publication, and should be weighted accordingly against the peer-reviewed findings elsewhere in this article; larger, peer-reviewed, longer-duration trials would be needed to independently verify these figures.

Multi-Trial Human Tolerability Review (Peer-Reviewed)

A peer-reviewed tolerability review aggregated data from six randomized, double-blind, placebo-controlled trials in a total of 893 adult human subjects. Across all trials, serum IGF-1 concentrations were not significantly altered by AOD-9604 relative to placebo, consistent with a mechanism independent of the canonical hGH receptor. Oral glucose tolerance was not negatively affected, no anti-AOD-9604 antibodies were detected in immunogenicity testing, and no withdrawal or serious adverse event attributable to AOD-9604 occurred across the pooled trials [4].

Genotoxicity and Toxicology Characterization

Genotoxicity testing spanned an Ames mutagenicity assay (bacterial, in vitro), a chromosomal aberration assay in Chinese hamster ovary (CHO) cells (in vitro), and a bone micronucleus assay within a 4-week mouse toxicology study — with no genotoxic activity observed across any assay. Chronic oral toxicology studies in Han Wistar rats (6 months) and cynomolgus monkeys (9 months) found no treatment-related deaths, clinically significant signs, or adverse changes in organ mass, ECG parameters, or histology at the concentrations tested. In vitro pharmacokinetic characterization in murine plasma found a half-life of approximately 4 minutes, reflecting rapid proteolytic degradation [5].

Intra-Articular Cartilage Research in Rabbits

This study used live New Zealand White rabbits in an in vivo osteoarthritis model — not an in vitro mouse model, correcting a species/method discrepancy found in some secondary summaries of this research.

Thirty-two rabbits were allocated across four groups receiving placebo, AOD-9604 alone, hyaluronic acid (HA) alone, or a combined AOD-9604/HA intervention over 4–7 weeks, with cartilage evaluated histopathologically afterward. The combined AOD-9604/HA group showed the least cartilage degeneration among the groups tested. Separately cited in vitro data suggested AOD-9604 may promote osteogenic differentiation of adipose-derived mesenchymal stem cells and stimulate proteoglycan/type II collagen production in bovine chondrocyte cultures [6].

Oncology Research: Nanoparticle-Based Delivery (In Vitro, Human Cell Line)

An in vitro study using MCF-7 human breast cancer cells examined whether AOD-9604 could potentiate doxorubicin's anti-proliferative activity when co-delivered via chitosan nanoparticles. Dual-loaded nanoparticles (doxorubicin + AOD-9604) showed greater anti-proliferative activity against MCF-7 cells than doxorubicin-loaded nanoparticles alone, with researchers proposing AOD-9604 may help doxorubicin engage additional protein targets within the cancer cells [7]. This remains an early exploratory in vitro finding requiring substantial further research before any broader interpretation.

Evidence Summary: Study Type and Model by Research Area

Storage and Stability

Key Takeaways

References

1. National Center for Biotechnology Information. PubChem Compound Summary for CID 71300630, AOD-9604. 2024. https://pubchem.ncbi.nlm.nih.gov/compound/71300630
2. Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-9. https://pubmed.ncbi.nlm.nih.gov/11713213/
3. Ng FM, Sun J, Sharma L, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-8. https://pubmed.ncbi.nlm.nih.gov/11146367/
4. Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab. 2013;3(1-2):7-15. https://www.jofem.org/index.php/jofem/article/view/157
5. Moré MI, Kenley D. Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health. J Endocrinol Metab. 2014;4(3):64-77. https://www.jofem.org/index.php/jofem/article/view/213/278
6. Kwon DR, Park GY. Effect of intra-articular injection of AOD9604 with or without hyaluronic acid in rabbit osteoarthritis model. Ann Clin Lab Sci. 2015;45(4):426-32. https://pubmed.ncbi.nlm.nih.gov/26275694/
7. Habibullah MM, Mohan S, Syed NK, et al. Human growth hormone fragment 176-191 peptide enhances the toxicity of doxorubicin-loaded chitosan nanoparticles against MCF-7 breast cancer cells. Drug Des Devel Ther. 2022;16:1963-1974. https://doi.org/10.2147/DDDT.S367586
8. Misra M. Obesity pharmacotherapy: current perspectives and future directions. Curr Cardiol Rev. 2013;9(1):33-54. https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/
9. Obesity drug codenamed AOD 9604 highly successful in trials. News-Medical.Net. 2004 Dec 16. (News report, not a peer-reviewed publication.) https://www.news-medical.net/news/2004/12/16/6878.aspx
10. National Center for Biotechnology Information. PubChem Compound Summary for CID 168310522, AOD-9604 Acetate. 2024. https://pubchem.ncbi.nlm.nih.gov/compound/168310522